Ivermectin has not been clinically tested in patients with lung cancer, so its safety profile in this group is unknown. The drug’s usual side effects include dizziness, rash, nausea, diarrhoea, muscle pain, and, in rare cases, liver or neurological problems. In cancer patients, especially those on chemotherapy or immunotherapy, these risks may be amplified due to weakened immunity and drug interactions. Because of this, patients should avoid self‑medicating and promptly report any adverse reactions to their oncologist, who can assess whether symptoms are related to ivermectin or cancer treatment and guide safe care.